A Phase 3 interventional study of Selpercatinib and Carboplatin in Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 196 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company — 6 open to participants now, 20 under way, 6 of them phase 3. Carcinoma, Non-Small-Cell Lung · Eli Lilly and Company.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 29th largest by enrollment of the 139 interventional ones that give a count, is one of 3 that started in 2020, is one of 25 in phase 3, reaches primary completion later than 4 of the 19 other live ones, and was the 131st registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →6 of the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Australia, Austria and 26 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, China and 5 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, France and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Austria and 26 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, France, Japan and 2 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 41 · Phase 2 86 · Phase 3 25 · Phase 4 3
First in 2000; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 261 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 109 across the 139 interventional studies, 1,076 across the 2 observational. Of the 121 that completed or were terminated, 81 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
5 of the studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
| NCT06238479Eli Lilly and CompanyA Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | 2027-03 |
| NCT04956640Eli Lilly and CompanyStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | 2027-04 |
| NCT06465069Eli Lilly and CompanyA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | 2027-05 |
| NCT06561685Eli Lilly and CompanyA Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Exclusion Criteria for Participants Receiving Pembrolizumab:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
160 milligram (mg) Selpercatinib administered orally twice daily (BID) continuously in 21-day cycles.
Drug: Selpercatinib
Pemetrexed 500 milligrams per meter squared (mg/m2) administered intravenously (IV) on Day 1, every 3 weeks (Q3W), plus investigator's choice of carboplatin area under the concentration versus time curve 5 (AUC 5 \[maximum dose of 750 mg\] IV), or cisplatin (75 mg/m2 cisplatin IV) on Day 1 Q3W for 4 cycles, plus investigator's choice with or without 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.
Drug: Carboplatin · Drug: Cisplatin · Drug: Pemetrexed · Drug: Pembrolizumab
Administered orally
Also known as: LY3527723, LOXO-292
Administered IV
Administered IV
Administered IV
Administered IV
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (With Pembrolizumab)
PFS is defined as the time from randomization until the occurrence of documented disease progression by the BICR, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, or death from any cause in the absence of BICR-documented progressive disease.
Time frame: Baseline to Progressive Disease or Death from Any Cause Up to 31 Months
PFS by BICR (With or Without Pembrolizumab)
PFS is defined as the time from randomization until the occurrence of documented disease progression by the BICR, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, or death from any cause in the absence of BICR-documented progressive disease.
Time frame: Baseline to Progressive Disease or Death from Any Cause Up to 31 Months
Percentage of Participant With Disease Control Rate (DCR) by BICR (With Pembrolizumab)
DCR by BICR (with Pembrolizumab) is defined as the number of participants who achieve a BOR of complete response (CR), partial response (PR), or stable disease (SD) lasting 16 or more weeks divided by the total number of participants randomized to each treatment arm.
Time frame: Baseline to Progressive Disease or Death from Any Cause Up to 31 Months
Percentage of Participant With DCR by BICR (With or Without Pembrolizumab)
DCR by BICR (with or without Pembrolizumab) is defined as the number of participants who achieve a BOR of CR, PR, or SD lasting 16 or more weeks divided by the total number of participants randomized to each treatment arm.
Time frame: Baseline to Progressive Disease or Death from Any Cause Up to 31 Months
PFS2 (With Pembrolizumab)
PFS2 is defined as the time from randomization to disease progression on the next line of treatment or death from any cause in the absence of observed disease progression.
Time frame: Baseline to Second Disease Progression or Death from Any Cause Up to 38 Months
PFS2 (With or Without Pembrolizumab)
PFS2 is defined as the time from randomization to disease progression on the next line of treatment or death from any cause in the absence of observed disease progression.
Time frame: Baseline to Second Disease Progression or Death from Any Cause Up to 38 Months
Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR (With Pembrolizumab)
ORR is defined as the number of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the total number of participants randomized to each treatment arm.
Time frame: Baseline through Disease Progression or Death Up to 31 Months
ORR: Percentage of Participants With CR or PR by BICR (With or Without Pembrolizumab)
ORR is defined as the number of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the total number of participants randomized to each treatment arm.
Time frame: Baseline through Disease Progression or Death Up to 31 Months
Duration of Response (DoR) by BICR (With Pembrolizumab)
DoR was defined as the time from the date that measurement criteria for CR or PR (whichever is first recorded) were first met until the first date that disease was recurrent or documented disease progression was observed, or the date of death from any cause in the absence of documented disease progression or recurrence. The DOR according to both BICR and investigator-assessed BOR was evaluated per RECIST 1.1 criteria.
Time frame: Date of CR or PR to Date of Disease Progression or Death Due to Any Cause Up to 31 Months
DOR by BICR (With or Without Pembrolizumab)
DoR was defined as the time from the date that measurement criteria for CR or PR (whichever is first recorded) were first met until the first date that disease was recurrent or documented disease progression was observed, or the date of death from any cause in the absence of documented disease progression or recurrence. The DOR according to both BICR and investigator-assessed BOR was evaluated per RECIST 1.1 criteria.
Time frame: Date of CR or PR to Date of Disease Progression or Death Due to Any Cause Up to 31 Months
Overall Survival (OS) (With Pembrolizumab)
Overall survival was defined as the time from randomization until death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data was censored on the last date the participant is known to be alive.
Time frame: Baseline to Date of Death from Any Cause Up to 38 Months
OS (With or Without Pembrolizumab)
Overall survival was defined as the time from randomization until death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data will be censored on the last date the participant is known to be alive.
Time frame: Baseline to Date of Death from Any Cause Up to 38 Months
Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 by BICR (With Pembrolizumab)
Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RECIST 1.1 by BICR (with Pembrolizumab)
Time frame: Baseline through Central Nervous System (CNS) Progression or Death up to 31 Months
Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST 1.1 by BICR (With or Without Pembrolizumab)
Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RECIST 1.1 by BICR (with or without Pembrolizumab)
Time frame: Baseline through CNS Progression or Death Up to 31 Months
Median Intracranial DOR Per RECIST 1.1 by BICR (With Pembrolizumab)
Intracranial DOR per RECIST 1.1 by BICR (with Pembrolizumab)
Time frame: Date of Intracranial CR or PR to Date of CNS Progression or Death Due to Any Cause Up to 31 Months
Median Intracranial DOR Per RECIST 1.1 by BICR (With or Without Pembrolizumab)
Median Intracranial DOR per RECIST 1.1 by BICR (with or without Pembrolizumab)
Time frame: Date of Intracranial CR or PR to Date of CNS Progression or Death Due to Any Cause Up to 31 Months
Time to Deterioration of Pulmonary Symptoms (With Pembrolizumab)
Time to Deterioration of Pulmonary Symptoms Measured by the NSCLC-Symptom Assessment Questionnaire (SAQ) (with Pembrolizumab)
Time frame: Baseline to Deterioration of Pulmonary Symptoms Up to 31 Months
Time to Deterioration of Pulmonary Symptoms (With or Without Pembrolizumab)
Time to Deterioration of Pulmonary Symptoms Measured by the NSCLC-SAQ (with or without Pembrolizumab)
Time frame: Baseline to Deterioration of Pulmonary Symptoms Up to 31 Months
The Concordance of the Local Lab and the Central Lab RET Results: Percentage of Participants With RET-Positive Specimens as Called by the Central Lab, Which is Also RET-Positive as Called by a Local Lab (Positive Percent Agreement)
The Concordance of the Local Lab and the Central Lab RET Results: Percentage of Participants with RET-Positive Specimens as Called by the Central Lab, which is also RET-Positive as Called by a Local Lab (Positive Percent Agreement)
Time frame: Baseline
Median Time to CNS Progression Per RECIST 1.1 by BICR (With Pembrolizumab)
Time to CNS Progression per RECIST 1.1 by BICR (with Pembrolizumab)
Time frame: Baseline through CNS Progression or Death Up to 31 Months
Median Time to CNS Progression Per RECIST 1.1 by BICR (With or Without Pembrolizumab)
Time to CNS Progression per RECIST 1.1 by BICR (with or without Pembrolizumab)
Time frame: Baseline through CNS Progression or Death Up to 31 Months
Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) by BICR (With Pembrolizumab)
Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RANO-BM by BICR (with Pembrolizumab)
Time frame: Baseline through CNS Progression or Death Up to 31 Months
Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RANO-BM by BICR (With or Without Pembrolizumab)
Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RANO-BM by BICR (with or without Pembrolizumab)
Time frame: Baseline through CNS Progression or Death Up to 31 Months
Intracranial DOR Per RANO-BM by BICR (With Pembrolizumab)
Intracranial DOR per RANO-BM by BICR (with Pembrolizumab)
Time frame: Date of Intracranial CR or PR to Date of CNS Progression or Death Due to Any Cause Up to 31 Months
Intracranial DOR Per RANO-BM by BICR (With or Without Pembrolizumab)
Intracranial DOR per RANO-BM by BICR (with or without Pembrolizumab)
Time frame: Date of Intracranial CR or PR to Date of CNS Progression or Death Due to Any Cause Up to 31 Months
| Milestone | Selpercatinib (TRT A) | Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) |
|---|---|---|
| Started | 159 | 102 |
| Received at least one dose of study drug | 158 | 98 |
| Completed | 61 | 70 |
| Not completed | 98 | 32 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: On treatment | 93 | 30 |
PFS is defined as the time from randomization until the occurrence of documented disease progression by the BICR, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, or death from any cause in the absence of BICR-documented progressive disease.
| Months | Selpercatinib (TRT A) | Pemetrexed and Platinum With Pembrolizumab (TRT B) |
|---|---|---|
| Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (With Pembrolizumab) | 24.84 (16.89 to NA) | 11.17 (8.77 to 16.76) |
PFS is defined as the time from randomization until the occurrence of documented disease progression by the BICR, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, or death from any cause in the absence of BICR-documented progressive disease.
| Months | Selpercatinib (TRT A) | Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) |
|---|---|---|
| PFS by BICR (With or Without Pembrolizumab) | 24.84 (17.31 to NA) | 11.17 (8.77 to 16.76) |
DCR by BICR (with Pembrolizumab) is defined as the number of participants who achieve a BOR of complete response (CR), partial response (PR), or stable disease (SD) lasting 16 or more weeks divided by the total number of participants randomized to each treatment arm.
| Percentage of Participants | Selpercatinib (TRT A) | Pemetrexed and Platinum With Pembrolizumab (TRT B) |
|---|---|---|
| Percentage of Participant With Disease Control Rate (DCR) by BICR (With Pembrolizumab) | 89.1 (82.5 to 93.9) | 84.3 (74.7 to 91.4) |
DCR by BICR (with or without Pembrolizumab) is defined as the number of participants who achieve a BOR of CR, PR, or SD lasting 16 or more weeks divided by the total number of participants randomized to each treatment arm.
| Percentage of Participants | Selpercatinib (TRT A) | Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) |
|---|---|---|
| Percentage of Participant With DCR by BICR (With or Without Pembrolizumab) | 89.3 (83.4 to 93.7) | 82.4 (73.6 to 89.2) |
PFS2 is defined as the time from randomization to disease progression on the next line of treatment or death from any cause in the absence of observed disease progression.
| Months | Selpercatinib (TRT A) | Pemetrexed and Platinum With Pembrolizumab (TRT B) |
|---|---|---|
| PFS2 (With Pembrolizumab) | NA (NA to NA) | NA (NA to NA) |
PFS2 is defined as the time from randomization to disease progression on the next line of treatment or death from any cause in the absence of observed disease progression.
| Months | Selpercatinib (TRT A) | Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) |
|---|---|---|
| PFS2 (With or Without Pembrolizumab) | NA (NA to NA) | NA (NA to NA) |
ORR is defined as the number of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the total number of participants randomized to each treatment arm.
| Percentage of participants | Selpercatinib (TRT A) | Pemetrexed and Platinum With Pembrolizumab (TRT B) |
|---|---|---|
| Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR (With Pembrolizumab) | 83.7 (76.2 to 89.6) | 65.1 (53.8 to 75.2) |
ORR is defined as the number of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the total number of participants randomized to each treatment arm.
| Percentage of Participants | Selpercatinib (TRT A) | Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) |
|---|---|---|
| ORR: Percentage of Participants With CR or PR by BICR (With or Without Pembrolizumab) | 83.6 (77.0 to 89.0) | 62.7 (52.6 to 72.1) |
DoR was defined as the time from the date that measurement criteria for CR or PR (whichever is first recorded) were first met until the first date that disease was recurrent or documented disease progression was observed, or the date of death from any cause in the absence of documented disease progression or recurrence. The DOR according to both BICR and investigator-assessed BOR was evaluated per RECIST 1.1 criteria.
| Months | Selpercatinib (TRT A) | Pemetrexed and Platinum With Pembrolizumab (TRT B) |
|---|---|---|
| Duration of Response (DoR) by BICR (With Pembrolizumab) | 24.18 (17.94 to NA) | 11.47 (9.66 to 23.26) |
DoR was defined as the time from the date that measurement criteria for CR or PR (whichever is first recorded) were first met until the first date that disease was recurrent or documented disease progression was observed, or the date of death from any cause in the absence of documented disease progression or recurrence. The DOR according to both BICR and investigator-assessed BOR was evaluated per RECIST 1.1 criteria.
| Months | Selpercatinib (TRT A) | Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) |
|---|---|---|
| DOR by BICR (With or Without Pembrolizumab) | 24.18 (17.94 to NA) | 11.99 (9.69 to 23.26) |
Overall survival was defined as the time from randomization until death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data was censored on the last date the participant is known to be alive.
| Months | Selpercatinib (TRT A) | Pemetrexed and Platinum With Pembrolizumab (TRT B) |
|---|---|---|
| Overall Survival (OS) (With Pembrolizumab) | NA (NA to NA) | NA (NA to NA) |
Overall survival was defined as the time from randomization until death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data will be censored on the last date the participant is known to be alive.
| Months | Selpercatinib | Pemetrexed and Platinum With or Without Pembrolizumab |
|---|---|---|
| OS (With or Without Pembrolizumab) | 33.05 (33.05 to NA) | NA (NA to NA) |
Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RECIST 1.1 by BICR (with Pembrolizumab)
| Percentage of participants | Selpercatinib (TRT A) | Pemetrexed and Platinum With Pembrolizumab (TRT B) |
|---|---|---|
| Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 by BICR (With Pembrolizumab) | 81 (58.1 to 94.6) | 57.1 (34.0 to 78.2) |
Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RECIST 1.1 by BICR (with or without Pembrolizumab)
| Percentage of participants | Selpercatinib (TRT A) | Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) |
|---|---|---|
| Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST 1.1 by BICR (With or Without Pembrolizumab) | 84.0 (63.9 to 95.5) | 50.0 (29.9 to 70.1) |
Intracranial DOR per RECIST 1.1 by BICR (with Pembrolizumab)
| Months | Selpercatinib (TRT A) | Pemetrexed and Platinum With Pembrolizumab (TRT B) |
|---|---|---|
| Median Intracranial DOR Per RECIST 1.1 by BICR (With Pembrolizumab) | NA (14.75 to NA) | NA (8.74 to NA) |
Median Intracranial DOR per RECIST 1.1 by BICR (with or without Pembrolizumab)
| Months | Selpercatinib (TRT A) | Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) |
|---|---|---|
| Median Intracranial DOR Per RECIST 1.1 by BICR (With or Without Pembrolizumab) | NA (9.53 to NA) | 13.40 (4.17 to NA) |
Time to Deterioration of Pulmonary Symptoms Measured by the NSCLC-Symptom Assessment Questionnaire (SAQ) (with Pembrolizumab)
| Months | Selpercatinib (TRT A) | Pemetrexed and Platinum With Pembrolizumab (TRT B) |
|---|---|---|
| Time to Deterioration of Pulmonary Symptoms (With Pembrolizumab) | NA (NA to NA) | 1.9 (0.7 to 6.6) |
Time to Deterioration of Pulmonary Symptoms Measured by the NSCLC-SAQ (with or without Pembrolizumab)
| Months | Selpercatinib (TRT A) | Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) |
|---|---|---|
| Time to Deterioration of Pulmonary Symptoms (With or Without Pembrolizumab) | NA (NA to NA) | 1.6 (0.7 to 4.9) |
The Concordance of the Local Lab and the Central Lab RET Results: Percentage of Participants with RET-Positive Specimens as Called by the Central Lab, which is also RET-Positive as Called by a Local Lab (Positive Percent Agreement)
Results for this outcome have not been posted.
Time to CNS Progression per RECIST 1.1 by BICR (with Pembrolizumab)
| Months | Selpercatinib (TRT A) | Pemetrexed and Platinum With Pembrolizumab (TRT B) |
|---|---|---|
| Median Time to CNS Progression Per RECIST 1.1 by BICR (With Pembrolizumab) | NA (NA to NA) | NA (NA to NA) |
Time to CNS Progression per RECIST 1.1 by BICR (with or without Pembrolizumab)
| Months | Selpercatinib (TRT A) | Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) |
|---|---|---|
| Median Time to CNS Progression Per RECIST 1.1 by BICR (With or Without Pembrolizumab) | NA (NA to NA) | NA (NA to NA) |
Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RANO-BM by BICR (with Pembrolizumab)
Results for this outcome have not been posted.
Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RANO-BM by BICR (with or without Pembrolizumab)
Results for this outcome have not been posted.
Intracranial DOR per RANO-BM by BICR (with Pembrolizumab)
Results for this outcome have not been posted.
Intracranial DOR per RANO-BM by BICR (with or without Pembrolizumab)
Results for this outcome have not been posted.
Collected over Baseline Up to 38 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Selpercatinib (TRT A) | 32/158 (20.3%) | 55/158 (34.8%) | 156/158 (98.7%) |
| Carboplatin or Cisplatin+Pemetrexed+/-Pembrolizumab (TRT B) | 17/98 (17.3%) | 23/98 (23.5%) | 97/98 (99%) |
| Event | Selpercatinib (TRT A) | Carboplatin or Cisplatin+Pemetrexed+/-Pembrolizumab (TRT B) |
|---|---|---|
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 7/158 | 0/98 |
| Hepatic function abnormalHepatobiliary disorders | 4/158 | 0/98 |
| AnaemiaBlood and lymphatic system disorders | 0/158 | 2/98 |
| NeutropeniaBlood and lymphatic system disorders | 0/158 | 2/98 |
| Intestinal obstructionGastrointestinal disorders | 1/158 | 2/98 |
| PyrexiaGeneral disorders | 2/158 | 2/98 |
| PneumoniaInfections and infestations | 3/158 | 2/98 |
| Platelet count decreasedInvestigations | 1/158 | 2/98 |
| Spinal cord compressionNervous system disorders | 0/158 | 2/98 |
| AscitesGastrointestinal disorders | 3/158 | 0/98 |
| Event | Selpercatinib (TRT A) | Carboplatin or Cisplatin+Pemetrexed+/-Pembrolizumab (TRT B) |
|---|---|---|
| Aspartate aminotransferase increasedInvestigations | 97/158 | 39/98 |
| Alanine aminotransferase increasedInvestigations | 95/158 | 39/98 |
| AnaemiaBlood and lymphatic system disorders | 18/158 | 57/98 |
| HypertensionVascular disorders | 76/158 | 7/98 |
| NauseaGastrointestinal disorders | 20/158 | 43/98 |
| DiarrhoeaGastrointestinal disorders | 69/158 | 24/98 |
| ConstipationGastrointestinal disorders | 34/158 | 39/98 |
| Dry mouthGastrointestinal disorders | 61/158 | 6/98 |
| Blood bilirubin increasedInvestigations | 59/158 | 1/98 |
| Decreased appetiteMetabolism and nutrition disorders | 27/158 | 33/98 |
Intent to Treat Population (ITT): All randomized participants, even if a participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol.
| Age, Continuous(years) | Selpercatinib (TRT A) | Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) | Total |
|---|---|---|---|
| Mean | 60.2 ± 11.3 | 60.8 ± 11.4 | 60.4 ± 11.3 |
| Sex: Female, Male(Participants) | Selpercatinib (TRT A) | Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) | Total |
|---|---|---|---|
| Female | 86 | 57 | 143 |
| Male | 73 | 45 | 118 |
| Race (NIH/OMB)(Participants) | Selpercatinib (TRT A) | Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 3 |
| Asian | 92 | 52 | 144 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 58 | 43 | 101 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 4 | 6 | 10 |
| Region of Enrollment(Participants) | Selpercatinib (TRT A) | Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) | Total |
|---|---|---|---|
| Hong Kong | 4 | 1 | 5 |
| Czechia | 0 | 1 | 1 |
| Russia | 1 | 2 | 3 |
| Greece | 2 | 0 | 2 |
| Netherlands | 2 | 1 | 3 |
| South Korea | 8 | 8 | 16 |
| China | 62 | 28 | 90 |
| Brazil | 7 | 1 | 8 |
| Poland | 0 | 1 | 1 |
| France | 2 | 4 | 6 |
| Argentina | 2 | 0 | 2 |
| Japan | 15 | 10 | 25 |
| Ukraine | 0 | 5 | 5 |
| Spain | 7 | 9 | 16 |
| Canada | 2 | 1 | 3 |
| Turkey | 8 | 0 | 8 |
| Belgium | 3 | 3 | 6 |
| Taiwan | 2 | 4 | 6 |
| Italy | 20 | 12 | 32 |
| Mexico | 4 | 1 | 5 |
| Israel | 1 | 4 | 5 |
| Australia | 2 | 2 | 4 |
| Germany | 5 | 4 | 9 |
Showing the first 100 of 196 sites across 26 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Feb 2020 to primary completion in May 2023, 38 months.
Results were first posted in Jun 2024, 1 year 1 month after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 38 months is close to that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selpercatinib
Carcinoma, Non-Small-Cell Lung →